Pacritinib

From WikiMD's free health, diet & wellness encyclopedia
Jump to navigation Jump to search

An orally bioavailable inhibitor of Janus kinase 2 (JAK2) and the JAK2 mutant JAK2V617F with potential antineoplastic activity. Pacritinib competes with JAK2 for ATP binding, which may result in inhibition of JAK2 activation, inhibition of the JAK-STAT signaling pathway, and so caspase-dependent apoptosis. JAK2 is the most common mutated gene in bcr-abl-negative myeloproliferative disorders; the JAK2V617F gain-of-function mutation involves a valine-to-phenylalanine modification at position 617. The JAK-STAT signaling pathway is a major mediator of cytokine activity.

Learn more about Pacritinib

Latest research - Pacritinib

PubMed
Clinical trials

External links

Wikipedia
Medicine icon
Medicine icon

This WikiMD article Pacritinib is a stub. If you are familiar with the topic Pacritinib, you can help us. Paid editors welcome!

 

Pacritinib is part of WikiMD's free ^articles!

^Pacritinib (article) is provided for informational purposes only. No expressed or implied warranties as to the validity of content.
WikiMD is not a substitute for professional advice. By accessing and using WikiMD you agree to the terms of use.
Templates etc. when imported from Wikipedia, are licensed under CC BY-SA 3.0. See full disclaimers.
W8MD weight loss logo

Ad. Tired of being overweight?. W8MD's physician weight loss program can HELP. Tele medicine available